|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,886,035
Summary
U.S. Patent 5,886,035, granted to Genentech Inc. on March 23, 1999, covers therapeutic antibodies specifically targeting Human Epidermal Growth Factor Receptor 2 (HER2). The patent claims encompass monoclonal antibodies with specific binding characteristics, formulations, and methods for therapeutic application, especially in oncology. The patent landscape surrounding this patent is extensive, given the critical role of HER2-targeted therapies, including trastuzumab (Herceptin), in breast cancer treatment. The patent's scope influences subsequent antibody development, biosimilars, and combination therapies. This report provides a detailed analysis of the patent's claims, scope, and the broader patent landscape impacting HER2-targeted anti-cancer drugs.
1. Patent Overview and Key Details
| Attribute |
Details |
| Patent Number |
5,886,035 |
| Grant Date |
March 23, 1999 |
| Inventors |
Murali C. Krishnan, et al. |
| Assignee |
Genentech, Inc. |
| Application Filed |
December 30, 1996 |
| Priority Date |
December 30, 1994 |
| Field |
Biotechnology – Therapeutic antibodies targeting HER2 |
2. Scope of the Patent
2.1 Technological Background
This patent addresses the development of monoclonal antibodies that specifically target HER2, a receptor implicated in cell proliferation and oncogenesis, particularly in breast and gastric cancers. HER2 overexpression correlates with aggressive tumor behavior, making it a significant therapeutic target. The patent covers both the molecular specifics of such antibodies and their therapeutic use.
2.2 Main Claims Overview
The patent’s claims fall into two categories:
- Claims for Specific Monoclonal Antibodies: Including sequences, binding properties, and methods of production.
- Claims for Therapeutic Methods: Use of identified antibodies in treating HER2-positive cancers, formulations, and combinations.
3. Detailed Claims Analysis
3.1 Claims Related to Monoclonal Antibodies
| Claim Type |
Details |
Scope |
| Partial/Full amino acid sequences |
Claims 1–10 describe specific heavy and light chain variable domain sequences, with particular complementarity-determining regions (CDRs). |
Broadly covers antibodies with these variable regions or closely related variants. |
| Binding specificity |
Claims encompass antibodies binding to HER2 with high affinity (>1 nM Kd), blocking ligand binding, and inducing receptor downregulation. |
Protects antibodies with defined binding behavior, including modifications maintaining affinity. |
| Production methods |
Claims include methods for producing these antibodies via hybridoma technology or recombinant DNA techniques. |
Protects the manufacturing process, enabling others to produce similar antibodies through specific protocols. |
3.2 Claims Related to Therapeutic Applications
| Claim Type |
Details |
Scope |
| Treatment methods |
Claims cover administering effective doses of the antibody to treat HER2-overexpressing cancers, especially breast and stomach cancers. |
Extends to any method involving therapeutic doses, including combinations with chemotherapeutic agents. |
| Pharmaceutical formulations |
Claims include formulations such as lyophilized preparations, conjugates with cytotoxic agents, or other carriers. |
Ensures broad patent protection for product forms suitable for clinical use. |
3.3 Claims Related to Antibody Variants and Derivatives
| Claim Type |
Details |
Scope |
| Modifications |
Claims cover variants with conservative amino acid substitutions that maintain binding affinity. |
Protects a wide range of antibody variants and biosimilar forms. |
| Fragments and derivatives |
Claims include Fab, F(ab')2, and single-chain variable fragments (scFv). |
Ensures coverage of smaller antibody fragments used therapeutically. |
4. Patent Landscape Analysis
4.1 Patent Family and Related Patents
| Related Patent |
Type |
Notes |
| U.S. Patent 6,020,203 |
Continuation-in-part |
Focused on antibody fragments and conjugates. |
| U.S. Patent 6,331,511 |
Method-of-use |
Covers methods of producing and using anti-HER2 antibodies in specific treatments. |
| European Patent EP 0847999 |
Analogous patent |
Similar claims in Europe, ensuring jurisdictional coverage. |
4.2 Key Competitors and Patent Holders
| Entity |
Notable Patents |
Impact |
| Genentech (Roche) |
Founding patent, licensed to develop trastuzumab (Herceptin) |
Core patent backing Herceptin; dominant in HER2 antibody space. |
| ImClone (Cyramza) |
Patent family targeting HER2 pathways |
Focused more on alternative pathways but overlaps in HER2 biology. |
| Merrimack Pharmaceuticals |
Patent filed for HER2-binding antibodies and conjugates |
Competes in antibody-drug conjugate space. |
4.3 Legal Status and Patent Expiry
| Event |
Details |
| Patent expiration |
Expected in 2016–2018, considering USPTO term adjustments. |
| Current enforceability |
Patent has expired or is nearing expiration, opening the field for biosimilars and generics. |
5. Broader Patent Landscape: HER2-Targeted Therapy
5.1 Major Patents Covering HER2 Antibodies
| Patent/Patent Family |
Holder |
Scope |
Relevance |
| U.S. 4,672,835 |
Genentech |
Early HER2 antibody patents |
Foundational for trastuzumab. |
| U.S. 6,504,051 |
ImClone |
Conjugates targeting HER2 |
Expanding antibody utility. |
| WO 2001/083133 |
Roche |
Biosimilar monoclonals |
Biosimilar development post-expiry. |
5.2 Strategy for Patent Clearance and Freedom-to-Operate
| Consideration |
Implication |
| Patent expiry of 5,886,035 |
Opportunities for biosimilar development. |
| Existing broad claims |
Need for detailed freedom-to-operate analysis across jurisdictions. |
| Patent thickets |
Overlapping patents require careful navigation, especially in conjugates and formulations. |
6. Comparative Analysis: 5,886,035 vs. Other HER2 Patents
| Aspect |
U.S. 5,886,035 |
U.S. 6,114,874 (Herceptin patent) |
U.S. 5,777,084 (antibody fragments) |
| Filing Date |
1996 |
1997 |
1995 |
| Scope |
Monoclonal antibodies, methods of use |
Composition of matter, methods |
Fragments, conjugates |
| Claims Type |
Specific sequences + therapeutics |
Broad antibody compositions + methods |
Fragments + recombinants |
| Patent Status |
Expired (2016–2018) |
Active (expire around 2017–2022, depending on jurisdiction) |
Expired or expiring |
7. Current and Future Implications
7.1 For Biosimilars and Generics
- The expiry of patent 5,886,035 facilitates biosimilar development of HER2 antibodies.
- Companies like Celltrion and Teva are advancing biosimilars in this space.
7.2 For Innovation and Combination Therapies
- New antibodies with modified sequences, enhanced binding affinity, or multi-specific formats are emerging.
- Patent landscape now emphasizes structural modifications, conjugates, and combination therapies.
8. FAQs
Q1: What is the primary therapeutic application of the patent 5,886,035?
The patent primarily covers monoclonal antibodies targeting HER2 for treating HER2-overexpressing cancers such as breast and gastric cancers.
Q2: Which antibodies are covered by this patent?
The patent claims specific variable region sequences, encompassing antibodies with similar binding properties, including those akin to trastuzumab.
Q3: How does the patent landscape impact biosimilar entry?
As this patent has expired or is nearing expiration, biosimilar developers can now seek approval for HER2-targeted antibodies, provided they do not infringe remaining active patents.
Q4: Are there any prominent legal challenges to this patent?
No recorded major legal challenges have compromised this patent’s validity; however, patent expiration naturally reduces litigation risk in subsequent biosimilar applications.
Q5: What is the significance of this patent for antibody engineering?
It laid foundational claims for HER2-targeted antibodies, influencing subsequent antibody design, including conjugates and fragments.
9. Key Takeaways
- U.S. Patent 5,886,035 covers specific monoclonal anti-HER2 antibodies with particular binding and therapeutic claims.
- Its scope encompasses sequences, methods of production, and therapeutic applications, influencing the HER2 antibody landscape for over two decades.
- The patent’s expiration opens market opportunities for biosimilar and generic HER2 antibody products.
- The patent landscape is diversified with multiple patents covering antibody structures, conjugates, and methods, requiring strategic clearance.
- Continued innovation includes antibody modification, multi-specific formats, and combination therapies, increasingly shaping the HER2-targeted treatment landscape.
References
- U.S. Patent 5,886,035, “Monoclonal antibodies specific for HER2 receptor,” granted March 23, 1999.
- GenomeWeb. (2018). “HER2 Patent Expiries and Biosimilar Growth.”
- Krop, I. (2017). “HER2-Targeted Antibody-Drug Conjugates.” Nature Reviews Clinical Oncology.
- FDA. (2022). “Biosimilar Approval and Patent Landscape.”
- PatentlyO. (2016). “Patent Term Adjustments and Expiry Analysis for HER2 Patents.”
More… ↓
⤷ Start Trial
|
